Subject of the day
AZN.L
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Line | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | $14.46B | $15.19B | $15.50B | $15.29B |
| Gross profit | $11.98B | $12.39B | $12.38B | $12.61B |
| Operating income | $3.51B | $3.58B | $2.98B | $4.25B |
| Net income | $2.45B | $2.53B | $2.33B | $3.08B |
| Diluted EPS | 1.57 | — | 1.49 | 1.97 |
| Free cash flow | $1.46B | $3.41B | $1.05B | $1.82B |
| CapEx | -$1.92B | -$1.73B | -$1.29B | -$1.54B |
$11,708.00
▲ +6.00 (+0.1%)
| 52w hi | $15,540.97 |
|---|---|
| 52w lo | $10,954.15 |
| Vol | 3.08M |
| As of | Aug 13 |
Our score -0.06
| Short | -0.61 |
|---|---|
| Medium | +0.04 |
| Long | +0.86 |
computed 2026-08-13
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
| Market cap | $181.58B |
|---|---|
| Enterprise value | $208.96B |
| Trailing P/E | 23.65x |
| Forward P/E | 13.83x |
| EV / EBITDA | 10.50x |
| P / S (ttm) | 2.96x |
| Profit margin | 17.0% |
| Return on equity | 22.0% |
| Revenue growth | +6.4% |
| Earnings growth | +2.5% |
| Debt / equity | 64.22 |
| Beta vs SPX | -0.12 |
|---|---|
| Corr SPX | -0.07 |
| Annual vol | 26.9% |
| Annual ret | -3.2% |
| Sharpe | -0.12 |
| Max DD | -28.2% |
Window: 504 trading days (491 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.56 | |
| Sector | +0.12 | |
| Technical | -0.28 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $11,706.00 | $11,746.00 | $11,604.00 | $11,708.00 | 3.08M |
| Aug 12 | $11,786.00 | $11,800.00 | $11,610.00 | $11,702.00 | 1.68M |
| Aug 11 | $11,980.00 | $12,058.00 | $11,838.84 | $11,844.00 | 2.71M |
| Aug 10 | $12,030.00 | $12,060.00 | $11,856.00 | $11,990.00 | 3.83M |
| Aug 7 | $11,898.00 | $12,096.00 | $11,854.00 | $11,896.00 | 12.68M |